Elicio Therapeutics AMPLIFY-7P data selected for ESMO 2026 oral slot
Elicio Therapeutics has confirmed that new pre-specified analyses from its randomised Phase 2 AMPLIFY-7P study of ELI-002 7P, also known as camupepimut, have been selected for a late-breaking Proffered Paper oral presentation at the European Society for Medical Oncology Congress 2026. The session is scheduled for 23 October in Madrid, where the data will be presented by Eileen M. O'Reilly of Memorial Sloan Kettering Cancer Center.
The AMPLIFY-7P trial enrolled 144 patients with mKRAS-driven pancreatic ductal adenocarcinoma across 24 US sites. The study did not meet its pre-specified primary endpoint of disease-free survival in the intent-to-treat population, a point the company acknowledged in the release. Elicio says the new analyses being presented at ESMO are pre-specified and are intended to shed further light on the clinical and biological activity of ELI-002 7P, and to support the design of a potential Phase 3 programme in the adjuvant setting.
What the data will need to show
Securing an oral slot at ESMO for a trial that missed its primary endpoint is notable, and reflects the strong scientific interest in KRAS-targeted immunotherapy as a field. The question for oncologists and investors attending the session will be whether the pre-specified subgroup or biomarker analyses reveal a patient population in which ELI-002 7P demonstrates a sufficiently robust signal to justify a larger, more focused randomised study.
Robert Connelly, president and chief executive of Elicio, said the findings "deepen our understanding of ELI-002 7P's clinical and biological activity and provide important direction as we refine the development strategy for a potential Phase 3 study in adjuvant pancreatic cancer."
ELI-002 7P is a seven-peptide formulation designed to elicit immune responses against seven common KRAS mutations. It uses Elicio's Amphiphile technology, which conjugates peptide antigens and an adjuvant to lipid-like structures that preferentially traffic to the lymph nodes, aiming to improve T cell priming relative to conventional peptide vaccines. The candidate is administered subcutaneously and is positioned as an off-the-shelf product, avoiding the manufacturing complexity and turnaround time associated with personalised neoantigen approaches.
Competitive and regulatory landscape
Pancreatic ductal adenocarcinoma remains one of the most intractable oncology indications, with five-year survival rates below 15% across all stages. The adjuvant setting presents a meaningful opportunity: patients who have undergone resection represent a defined population with measurable residual disease burden, making them a logical target for immunotherapy that aims to promote durable cancer immunosurveillance.
The KRAS mutation space has attracted considerable activity in recent years. Small-molecule KRAS inhibitors, including approved agents in colorectal and lung cancer, have shifted market expectations around KRAS-driven tumours, though pancreatic cancer has proven more resistant. Therapeutic cancer vaccines and peptide-based immunotherapies face a higher bar following mixed results across multiple programmes. Elicio's ability to define a responsive subgroup at ESMO will be critical to its argument for advancing to Phase 3 and to any partnering discussions that may follow. The company's pipeline also includes ELI-007, targeting BRAF-driven cancers, and ELI-008, directed at p53 hotspot mutations, giving it additional options if the PDAC programme requires a redesign.